KALA BIO, Inc. (KALA): Nasdaq/NYSE listing notice — KALA BIO receives Nasdaq deficiency notice for MVLS below $35M; 180 days to comply

KALA BIO, Inc.

Nasdaq notified KALA BIO on Nov 10, 2025 that MVLS was below $35M for 30 consecutive business days, violating Listing Rule 5550(b)(2).
Company also fails alternative standards: stockholders' equity <$2.5M and no net income from continuing operations in recent fiscal years.
Has until May 11, 2026 to regain compliance; if MVLS is at least $35M for 10 consecutive days, compliance is restored.
If not compliant by the deadline, stock subject to delisting; company may appeal to a Nasdaq Listing Qualifications Panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

KALA BIO, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2), 5810(c)(3)(C)

Exact text from the filing

November 10, 2025, KALA BIO, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the “Minimum MVLS Requirement”) for continued listing on The Nasdaq Capital Market, as the market value of the Company’s listed securities was less than $35 million for the previous 30 consecutive business days. As of the date of this Current Report on Form 8-K, the Company does not meet the alternative sta

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-110316

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.